Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesFRA:IX1 +3.30%98 EV-to-EBITDA is 30.11 as of Jul. 29, 2026, which is 17% below its 10-year median of 36.09. GuruFocus rates FRA:IX1 with a GF Score™ of 98/100 and a GF Value™ of €552.15 (Modestly Undervalued). Among 118 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 75.42% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IDEXX Laboratories's enterprise value is €40,315 Mil.
IDEXX Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €1,339 Mil. Therefore, IDEXX Laboratories's EV-to-EBITDA for today is 30.11.
The historical rank and industry rank for IDEXX Laboratories's EV-to-EBITDA or its related term are showing as below:
FRA:IX1'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 24.9 Med: 36.09 Max: 63.17
Current: 29.43
During the past 13 years, the highest EV-to-EBITDA of IDEXX Laboratories was 63.17. The lowest was 24.90. And the median was 36.09.
FRA:IX1's EV-to-EBITDA is ranked worse than 75.42% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.53
vs FRA:IX1: 29.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IDEXX Laboratories's PE Ratio (TTM) for today is calculated as:
IDEXX Laboratories's share price for today is €494.70.
IDEXX Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.676.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for IDEXX Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's EV-to-EBITDA falls into.
IDEXX Laboratories's current Enterprise Value is €40,315 Mil.
IDEXX Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,339 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (FRA:IX1) has a EV-to-EBITDA of 30.11 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IDEXX Laboratories. This is 17% below median its historical median of 36.09. Over the past decade, IDEXX Laboratories' EV-to-EBITDA has ranged from 24.90 to 63.17. According to the industry distribution chart, IDEXX Laboratories ranks #89 out of 118 companies in the Medical Diagnostics & Research industry, placing it in the top 75.4%.
Is IDEXX Laboratories' EV-to-EBITDA too high?
IDEXX Laboratories' current EV-to-EBITDA of 30.11 is 17% below median its 10-year median of 36.09. Over the past 10 years, this metric has ranged from a low of 24.90 to a high of 63.17. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.53. IDEXX Laboratories' value of 30.11 is 93.9% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #89 out of 118 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' EV-to-EBITDA compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #89 out of 118 companies for EV-to-EBITDA. This places IDEXX Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 15.53. IDEXX Laboratories' value of 30.11 is 93.9% above this benchmark. Historically, IDEXX Laboratories' own EV-to-EBITDA has ranged from 24.90 to 63.17 over the past decade. While the company's 10-year median is 36.09 vs. the industry median of 15.53, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.53, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current EV-to-EBITDA of 30.11 is 93.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IDEXX Laboratories. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current EV-to-EBITDA is 30.11, which is 17% below median its own 10-year median of 36.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €552.15, compared to a current price of €494.70 — trading 10.4% below its estimated fair value. The current EV-to-EBITDA is 30.11, which is 17% below median its 10-year median of 36.09 and 93.9% above the Medical Diagnostics & Research industry median of 15.53. IDEXX Laboratories' overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current EV-to-EBITDA is 30.11 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €494.70 is trading 10.4% below its estimated GF Value™ of €552.15.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
EV-to-EBITDA: 30.11 (17% below median its 10-year median of 36.09)
GF Value™: €552.15 vs. price of €494.70 (10.4% below fair value)
Industry Position: 93.9% above the Medical Diagnostics & Research median (#89 of 118)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
98GF Score
Get the complete analysis for FRA:IX1
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
